2,3,4-octanetriol | 36283-98-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2,3,4-octanetriol
• 英文别名: Octan-2,3,4-triol；Octane-2,3,4-triol
• CAS: 36283-98-4
• 化学式: C₈H₁₈O₃
• 分子量: 162.229
• InChiKey: WAFOSDMKSJGJBX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  60.7
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  (E)-oct-2-en-4-ol 、 二氧化碳 生成 2,3,4-octanetriol
  参考文献：
  名称：

  Regio- and stereocontrolled synthesis of epoxy alcohols and triols from allylic and homoallylic alcohols via iodocarbonates

  摘要：

  DOI：

  10.1021/jo00145a004

文献信息

• [EN] GLUCOPYRANOSYL DERIVATIVES AND THEIR USES IN MEDICINE<br/>[FR] DÉRIVÉS DE GLUCOPYRANOSYL ET LEURS UTILISATIONS EN MÉDECINE
  申请人：SUNSHINE LAKE PHARMA CO LTD

  公开号：WO2015043511A1

  公开（公告）日：2015-04-02

  Disclosed are glucopyranosyl derivatives used as sodium dependent glucose cotransporters (SGLTs) inhibitors, intermediates or preparation processes thereof, and pharmaceutical uses thereof, especially glucopyranosyl derivatives represented by Formula (I), or pharmaceutically acceptable salts or all stereoisomers thereof, pharmaceutical compositions containing these derivatives and their uses for treatment of diabetes and diabetes-related diseases.

  揭示了作为钠依赖性葡萄糖共转运蛋白（SGLTs）抑制剂使用的葡萄糖吡喃糖苷衍生物，其中间体或制备过程，以及其药用用途，特别是由式（I）表示的葡萄糖吡喃糖苷衍生物，或其所有立体异构体的药用可接受盐，含有这些衍生物的药用组合物及其用于治疗糖尿病和糖尿病相关疾病的用途。
• [EN] DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES<br/>[FR] DÉRIVÉS DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL
  申请人：PFIZER

  公开号：WO2011051864A1

  公开（公告）日：2011-05-05

  Compounds of Formula (A) and (B) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors).

  本文描述了化合物(A)和(B)的化学式及其用途，用于治疗由钠葡萄糖转运体抑制剂（特别是SGLT2抑制剂）介导的疾病、症状和/或紊乱。
• [EN] SOLID FORMS OF ERTUGLIFLOZIN FREE BASE AND SOLID DISPERSIONS COMPRISING ERTUGLIFLOZIN L-PYROGLUTAMIC ACID.<br/>[FR] FORMES SOLIDES DE BASE LIBRE D'ERTUGLIFLOZINE ET DISPERSIONS À L'ÉTAT SOLIDE COMPRENANT DE L'ACIDE ERTUGLIFLOZIN L-PYROGLUTAMIQUE
  申请人：MSN LABORATORIES PRIVATE LTD R&D CENTER

  公开号：WO2020026273A1

  公开（公告）日：2020-02-06

  The present invention related to novel crystalline forms of (1S, 2S, 3S, 4R, 5S)-5-(4-chloro-3-(4-ethoxybenzyl) phenyl)-1-(hydroxymethyl)-6,8-dioxabicyclo [3.2.1] octane-2,3,4-triol free base of formula (I) and process for their preparation thereof. The present invention also relates to amorphous, solid dispersions of (1S, 2S, 3S, 4R, 5S)-5-(4-chloro-3-(4-ethoxybenzyl) phenyl)-1-(hydroxymethyl)-6,8-dioxabicyclo [3.2.1] octane-2,3,4-triol L-pyroglutamic acid of formula (II) and process their preparation thereof.

  本发明涉及公式（I）的（1S，2S，3S，4R，5S）-5-（4-氯-3-（4-乙氧基苯基甲基）苯基）-1-（羟甲基）-6,8-二氧杂双环[3.2.1]辛烷-2,3,4-三醇游离碱的新晶体形式及其制备方法。本发明还涉及公式（II）的（1S，2S，3S，4R，5S）-5-（4-氯-3-（4-乙氧基苯基甲基）苯基）-1-（羟甲基）-6,8-二氧杂双环[3.2.1]辛烷-2,3,4-三醇L-谷氨酸的非晶态、固体分散体及其制备方法。
• NOVEL ENZYME
  申请人：DAVIS Benjamin Guy

  公开号：US20100086958A1

  公开（公告）日：2010-04-08

  Novel FDH enzymes are provided herein, including novel NADPH-specific and NADH-specific FDH enzymes. Additionally, methods are provided utilizing these novel enzymes in catalytic systems for in situ regeneration of NADPH or NADH. Further aspects of the invention relate to the definition and use of crystal structures of these novel enzymes.

  本文提供了新颖的FDH酶，包括新颖的NADPH特异性和NADH特异性FDH酶。此外，提供了利用这些新颖酶在催化系统中进行NADPH或NADH原位再生的方法。本发明的进一步方面涉及这些新颖酶的晶体结构的定义和使用。
• C-ARYL GLUCOSIDE DERIVATIVES, PREPARATION RPOCESS AND PHARMACEUTICAL USE THEREOF
  申请人：Shanghai Hengrui Pharmaceutical Co. Ltd.

  公开号：EP2604612A1

  公开（公告）日：2013-06-19

  Disclosed are C-aryl glucoside derivatives, preparation processes and pharmaceutical uses thereof, especially C-aryl glucoside derivatives represented by formula (I), pharmaceutical salts or all stereoisomers thereof, their preparation methods, pharmaceutical compositions containing the derivatives and their uses as therapeutic agents, especially as sodium-dependent glucose cotransporter(SGLT)-1 inhibitors, wherein each substituent of formula (I) is defined in the specification.

  公开了 C-芳基葡萄糖苷衍生物、其制备工艺和药物用途，特别是式 (I) 所代表的 C-芳基葡萄糖苷衍生物、其药物盐或所有立体异构体、其制备方法、含有这些衍生物的药物组合物及其作为治疗剂的用途，特别是作为钠依赖性葡萄糖共转运体 (SGLT)-1 抑制剂的用途，其中式 (I) 的每个取代基在说明书中定义。